Role of Ayurveda in Multi Drug Resistant Pulmonary Tuberculosis.
- Conditions
- Health Condition 1: Z111- Encounter for screening for respiratory tuberculosis
- Registration Number
- CTRI/2023/08/056035
- Lead Sponsor
- Institute of Teaching and Research in Ayurveda Jamnagar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients willing to comply with all study procedures and availability for the duration of the study.
2.Patients having Rifampsin resistance or Isoniazid resistance.
3.Patients with primary and acquired resistance to MTB.
1.Patients having uncontrolled cardiac, renal, hepatic disease, HIV-AIDS, malignancy, cancer and other associated lung disease.
2.Pregnant and lactating women.
3.Patients who are getting first line (primary DS PTB) Anti tubercular treatment.
4.MDR PTB patients whose acute illness required intensive care.
5.Patient who are intolerated to ATD regimen
6.Extra pulmonary PTB patients will be excluded
7.Patients having both Rifampsin and Isoniazid or any other drug resistance from the ATD regimen.
8.Patients with longer (18-24 months) ATD regimen.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that the trial drug will improve the outcome in the patients of MDR PTB (Rajyakshma) in terms of early reduction of symptoms & toxic effects of ATT like cough, fever, hemoptysis, dyspnoea, chest pain etc. & atleast one grade decline in AFB smear.Timepoint: 12 weeks
- Secondary Outcome Measures
Name Time Method The trial drug will have a positive effect on health related quality of life in the patients of MDR PTB (Rajyakshma) in terms of physical, psychological, social & environmental parameter and nutritional status of the patient.Timepoint: 12 weeks